Metronomic Chemotherapy
Pharmacology and Clinical Applications
Published on 26. September 2014
Book
Hardback
XVI, 295 pages
978-3-662-43603-5 (ISBN)
Description
This book analyzes all aspects of metronomic chemotherapy, a new approach involving low-dose, long-term, and frequently administered therapy that has preclinical and clinical activity in various tumors. After an opening section on the pharmacological bases of metronomic chemotherapy, including its antiangiogenic effects and impact on immunity, preclinical studies on various classes of drug are discussed. Clinical applications of metronomic chemotherapy in a wide variety of tumors are then addressed in detail, with description of the results of all published studies. The clinical pharmacology of metronomic chemotherapy is also considered in depth, encompassing pharmacokinetics, pharmacogenetics, pharmacoeconomics, and adverse drug reactions. The book closes by describing the role of this therapy in the veterinarian clinic.
More details
Edition
2014 ed.
Language
English
Place of publication
Berlin
Germany
Publishing group
Springer Berlin
Target group
Professional and scholarly
Professional/practitioner
Illustrations
13 farbige Abbildungen, 9 s/w Abbildungen
XVI, 295 p. 22 illus., 13 illus. in color.
Dimensions
Height: 23.5 cm
Width: 15.5 cm
Weight
646 gr
ISBN-13
978-3-662-43603-5 (9783662436035)
DOI
10.1007/978-3-662-43604-2
Schweitzer Classification
Other editions
Additional editions
Book
09/2016
Springer
€117.69
Shipment within 7-9 days
E-Book
09/2014
1st Edition
Springer
€96.29
Available for download
Content
Part I: Pharmacological bases of metronomic chemotherapy: The metronomic concept.- Antiangiogenic effects of metronomic chemotherapy.- Effects of metronomic chemotherapy on immunity.- Other proposed mechanism of action of metronomic chemotherapy. Part II: Preclinical studies of metronomic chemotherapy: Alkylating agents.- Camptothecins.- Fluoropyrimidines.- Taxanes.- Vinca alkaloids.- Anthracyclines.- Other drugs.- Part III. Drugs combined with metronomic chemotherapy in preclinical studies: Tyrosine kinase inhibitors.- Monoclonal antibodies.- Tumor vaccines.- Other drugs. Part IV. Clinical activity of metronomic chemotherapy: Breast cancers.- Prostate cancers.- Gastrointestinal cancers.- CNS cancers.- Pediatric malignancies.- Sarcomas.- Hematological cancers.- Liver cancers.- Gynecologic Cancers.- Lung cancers.- Other cancers. Part V: Clinical Pharmacology of metronomic chemotherapy: Pharmacokinetics of metronomic chemotherapy.- Pharmacodynamics of metronomic chemotherapy.- Pharmacogenetics of metronomic chemotherapy.- Pharmacoeconomics of metronomic chemotherapy and its social impact.- Adverse drug reactions of metronomic chemotherapy. Part VI: Metronomic chemotherapy in veterinarian clinic: Clinical studies of metronomic chemotherapy alone.- Clinical studies of metronomic chemotherapy and other drugs.